A s s e s s m e n t o f r i s k f a c t o r s
Blood pressure, height, weight and body mass index; clinical diagnoses of hypertension, myocardial infarction, coronary artery disease, and diabetes mellitus; determination of congestive heart failure (CHF) diagnosis (validated using Framingham criteria); and preclinical diastolic or systolic dysfunction (no diagnosis of CHF, but with either diastolic or systolic dysfunction determined by echocardiography) were measured. Systolic function was categorized by ejection fraction (EF) ≤ 50% and ≤ 40%. Diastolic function was categorized as mild (impaired relaxation without increased filling pressures), moderate (impaired relaxation associated with moderate elevation of filling pressures or pseudonormal filling), or severe (advanced reduction in compliance or reversible or fixed restrictive filling). 2 Doppler criteria were required for the classification of moderate or severe diastolic dysfunction. Patients fulfilling only 1 criterion or with borderline variables for diastolic dysfunction were classified as "indeterminate."
M a i n o u t c o m e m e a s u r e s
Risk for all-cause mortality associated with diastolic dysfunction.
M a i n r e s u l t s
Of 1799 patients with determined normal or abnormal diastolic function, 502 patients (28%) had abnormal diastolic function (mild [21%], moderate [6.6%], and severe [0.7%]). 263 patients had indeterminate diastolic function. Diastolic dysfunction increased with increasing age and the presence of cardiovascular disease, diabetes, and systolic dysfunction. A greater increase in mortality occurred in patients with mild, moderate, or severe diastolic dysfunction than in patients with normal diastolic function (Table) . Overall, 123 patients (6%) had any systolic dysfunction (EF ≤ 50%) and 40 patients (2%) had moderate to severe systolic dysfunction (EF ≤ 40%). Framingham validated CHF was diagnosed in 45 patients (2.2%, 95% CI 1.6 to 2.8).
C o n c l u s i o n
Mild, moderate, or severe diastolic dysfunction was associated with increased all-cause mortality. 
C o m m e n t a r y
The study by Redfield and colleagues lends further support to the concept that diastolic dysfunction is prevalent, causes symptoms of CHF, and is associated with increased mortality. Diastolic dysfunction refers to a pathologically noncompliant left ventricle (LV) in diastole, which is the result of the combination of slowed LV relaxation and increased stiffness caused by hypertension, diabetes, ischemia, or a combination (1) .
The study uses a model of diastolic dysfunction that assumes temporal progression of dysfunction from mild to moderate to severe based on left-heart filling patterns obtained by state-of-the-art echo-Doppler techniques. Some aspects of this approach are problematic. The temporal progression of diastolic dysfunction has not been shown, the use of echo-Doppler parameters was obtained at only a single point in time, and the use of these filling patterns to reflect LV properties in a wide range of patients is not the standard of measurement. Although these limitations should be addressed in future research, the findings of this study are very useful.
Of interest, the prevalence of diastolic dysfunction in patients ≥ 65 years of age was 54%. This high prevalence probably resulted from inclusion of patients with age-related stiffening of the LV. It may be possible to exclude these patients by age-adjusting the echo-Doppler criteria; however, the decision to do this would depend on whether aging is considered to be normal or pathological.
In this study, the correlation of diastolic dysfunction with mortality appropriately corrects for age, sex, and EF, but fails to control for the direct effects of hypertension and diabetes mellitus on mortality. One might expect the direct effects of hypertension and diabetes mellitus to be substantial compared with their indirect effects through diastolic dysfunction. Such an analysis would be worthwhile. Despite this limitation, the study is an important effort toward recognizing the prevalence and significance of diastolic dysfunction, and particularly the prevalence of preclinical diastolic dysfunction. This knowledge should lead to the acceleration of efforts to devise a practical treatment regimen.
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